Michael was watching the news along with his main investors, Antoinette and Bridget. Other investors joined through a virtual eting and they all expressed their shock to him.
"I'm so shocked…it really worked, your pill."
"So does that an others will work?"
"We won't know for sure," Michael addressed the investors at the virtual conference. "But one thing I can assure you is that I can deliver what I promise, it only needs to be proved."
Michael continued. "This is a significant milestone, yes, but it's also just the beginning. There's a long road ahead to replicate these results in larger, more diverse groups."
"I'm sure you all guys want to see if your investnts are going to have a return, and I believe we're on the right path," Michael added, trying to bolster the confidence of his investors.
"Michael, while the initial results are promising, we need to think strategically about public perception and the scientific community's acceptance. How are we preparing for potential pushback or skepticism from the dical field?"
"That's an excellent point, Bridget," Michael responded, acknowledging her concern. "We're currently drafting publications for peer-reviewed journals and planning presentations at major dical conferences. By engaging directly with the dical community and sharing our data transparently, we aim to build credibility and foster trust."
Antoinette, always focused on the practicalities, interjected, "What about the manufacturing scale-up? Assuming the trials continue to yield positive results, are we prepared to et potential demand?"
Michael nodded, switching to a slide detailing the scale-up plan. "We've already started the groundwork for scaling up production. Thanks to your investnts we acquired facilities that can facilitate the initial batches and have started negotiations with external manufacturers to ensure we can ramp up quickly once we receive the necessary regulatory approvals."
"What about the dipod?" asked by another investor.
"The dipod, well we have approved for human trials. That trial is going to be held later in the evening at The Benavides Cancer Institute, University of Santo Tomas Hospital. We already have our oncologists there who are trained to use the dipod. The patient is a female in her mid-forties with Stage 4 breast cancer.
This is one of the most aggressive forms of cancer, and typically, options beco limited at this stage due to the spread of the cancer to other parts of the body."
Michael continued, "The dipod is designed to deliver targeted therapy using advanced nanotechnology. This allows us to deliver treatnt directly to the cancer cells, which should limit damage to surrounding healthy tissues and enhance the efficacy of the treatnt."
The investor nodded, clearly intrigued. "And if this trial succeeds?"
"If this trial succeeds," Michael replied, "it will not only validate the dipod as a viable treatnt option for advanced cancer stages, but it could fundantally change the way we treat cancer globally. Rember there are over 57 million people. A minority of them are like you, rich but have no chance of getting better with current treatnts.
The dipod could offer them hope and a better quality of life. Also, statistics said that in a year almost 10 million people are diagnosed with cancer worldwide. If we can make a significant impact even on a small percentage of these cases, the implications are monuntal, both from a healthcare perspective and a financial one."
Michael's statent resonated with the investors. They understood the potential of a successful dipod trial not just as a breakthrough in dical technology but also as a strategic investnt. The possibility of revolutionizing cancer treatnt was within reach, and the stakes were incredibly high.
"Plus, with the increasing incidence of cancer globally, the demand for innovative treatnts like the dipod is only going to grow," Michael added, emphasizing the urgency and importance of their work. "Our mission is to be at the forefront of this, leading the way with a treatnt that could potentially save millions of lives in the coming years."
The investors exchanged looks of agreent and anticipation.
"Very well, Mr. Michael. We will wish ourselves good luck with the result of the test of the dipod that will be conducted later in the evening," said the investor before leaving the virtual conference eting.
***
Six o'clock in the evening, December 1st, 2026.
In the Benavides Cancer Institute, University of Santo Tomas Hospital, a girl nad Marian was being transported in a wheelchair to a room where the dipod was installed. Marian appeared fragile, her pale complexion hinting at the strenuous battle she was enduring with stage 4 breast cancer.
In her forties, she had a subdued aura, with her thin fra wrapped in a hospital gown, her once vibrant eyes now looked weary.
As she entered the room, she saw a pod dominating the center. The machine looked more like sothing out of a science fiction movie than a dical device, with its array of sensors and robotic arms poised to deliver treatnt.
"Good evening, Marian. I'm Dr. Villanueva, and I'll be overseeing your treatnt today. I understand this can be a lot to take in, but I'm here to help you through every step."
Marian nodded slightly, her voice soft. "Thank you, Doctor. It's all a bit overwhelming."
"You don't know what that is right?" Villanueva asked as he glanced at the dipod.
Marian nodded weakly.
"That's a machine that can potentially save your life. You have volunteered to partake in this trial for a new treatnt called the dipod. It uses cutting-edge technology to target cancer cells precisely, without harming the surrounding healthy tissues," Dr. Villanueva explained, pointing to the sophisticated device.
"It's designed to deliver concentrated therapy directly to the problematic areas, which should significantly reduce the side effects typically associated with traditional cancer treatnts."
Marian looked at the device with a mix of fear and hope. "So, it targets only the cancer cells?"
"Yes, exactly," Dr. Villanueva confird. "The dipod uses nanoparticles that are programd to identify and attach to cancer cells specifically. Once attached, they release a treatnt that kills the cancer cells directly. This targeted approach helps to preserve healthy cells and reduce overall toxicity."
"Are you feeling hopeful?" Villanueva asked.
"I want to live long and see my children grow," Marian responded.
Dr. Villanueva gave her an encouraging smile. "That's what we're aiming for," he said. "We'll do everything we can to help you."
As Marian settled into the dipod, the room filled with the quiet hum of the machine powering up. Dr. Villanueva and his team made the final checks on the equipnt and monitored the displays closely.
"Okay, Marian, we're going to start the treatnt now," Dr. Villanueva announced. "You might feel a little cold from the cooling system inside the pod, but it shouldn't be uncomfortable."
Marian nodded, taking a deep breath as she braced herself. The dipod's lid closed gently, encapsulating her in its high-tech embrace. Inside, the machine was surprisingly comfortable, designed to reduce any claustrophobic feelings a patient might experience.
Before Villanueva's team could start the treatnt, Marian prayed to the almighty.
Reviews
All reviews (0)